Ritu Garg, MD
Lower target LDL-C cuts risk of CV events in ischemic stroke patients
April 23, 2021
Is a target LDL cholesterol (LDL-C) level of less than 70 mg/dL superior to a target LDL-C level of 90-110 mg/dL in prevention of future cardiovascular (CV) events in patients with a prior stroke of atherosclerotic origin or transient ischemic attack (TIA)?
Assessing the efficacy and safety of dapagliflozin in patients with HFrEF
April 22, 2021
Can the use of dapagliflozin, in addition to guideline-directed medical therapy, improve patient-reported outcomes and health-related quality of life in patients with heart failure and reduced ejection fraction (HFrEF)?